Evidence map›Paper›PMID 39665226›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Implantable Ultrasound-Powered MXene/PVA Hydrogel-Based Generator for Treatment of Glioblastoma.

Xiaoping Hu, Ziyi Qiu, Yilin Yang, Ting Xu, Kai Sheng, Weicheng Lu, Jingdun Xie, Bingzhe Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoping HuSchool of Biomedical Engineering, Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou, 510275, P. R. China.
Ziyi QiuSchool of Biomedical Engineering, Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou, 510275, P. R. China.
Yilin YangFaculty of Engineering, Department of Electrical and Electronic Engineering, The University of Hong Kong, Pokfulam, Hong Kong SAR, 999077, P. R. China.
Ting XuSchool of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, No.66, Gongchang Road, Guangming District, Shenzhen, 518107, P. R. China.
Kai ShengSchool of Biomedical Engineering, Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou, 510275, P. R. China.
Weicheng LuDepartment of Anesthesiology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Jingdun XieDepartment of Anesthesiology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Bingzhe XuSchool of Biomedical Engineering, Sun Yat-sen University, No. 135, Xingang Xi Road, Guangzhou, 510275, P. R. China.ORCID https://orcid.org/0000-0003-3007-5655

Funding

Foundation of Guangdong Provincial Key Laboratory of Sensor Technology and Biomedical Instrument 2020B1212060077National Natural Science Foundation of China 32101160Science Fund for Distinguished Young Scholars of Guangdong Province 2019B151502010
6 · The paper itself

Abstract

Glioblastoma (GBM) is a lethal disease with a poor prognosis due to its strong infiltration, which makes it difficult to remove completely. In this study, an implantable, modulus-tunable, and ultrasound-powered MXene/PVA hydrogel-based tumor treatment device (UP-MPH-TTD), which generates specific electromagnetic alternating fields that disrupt the mitosis of cancer cells without adversely affecting normal neurons is developed. The MXene/PVA hydrogel is used to form a tumor treatment field due to its high biocompatibility, excellent flexibility, and high conductivity, which improves ultrasonic electrical conversion efficiency and significantly reduces the size of the equipment. The implantable UP-MPH-TTD is wirelessly ultrasound-powered, small-sized, lightweight, and simply structured, significantly boosting therapeutic efficiency and reducing restrictions on patient movement. In vitro and in vivo experiments confirmed the device's therapeutic effect, demonstrating a ≈92% inhibition rate in the growth of clinical tumor cells and a 73% reduction in tumor area in tumor-bearing mice. The promising results indicate the broad application potential of the device in the treatment and prognostic improvement of GBM.

Indexed as

Brain NeoplasmsGlioblastomaHydrogelsAnimalsCell Line, TumorHumansMiceNitritesTransition ElementsHydrogelsMXeneNitritesTransition ElementsglioblastomaMXene/PVA hydrogelTTFultrasound‐powered

Identifiers

PMID39665226
PMCPMC11791951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.